In different cell lines derived from NSCLC, the combined effect of RNA interference targeting the EGFR mRNA, and inactivation of EGFR signaling using different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab were investigated. This evidence concerns the gene EGFR and non-small cell lung carcinoma.